| Name | Title | Contact Details |
|---|
Whole Biome`s mission is to be the trusted brand in bringing the public improved health solutions through microbiome interventions. We are developing microbiome diagnostics and interventions using our proprietary discovery platform.
Talis is developing a new class of diagnostic platform to enable rapid, high-complexity testing across a wide range of healthcare settings.
Nohla Therapeutics is a cellular therapy company driven to provide leading off the shelf therapies for patients with critical diseases. Nohla’s first product is a universal donor cell therapy targeting hematopoietic recovery and chemotherapy induced neutropenia, and is being extended to treat a range of other medical indications. This and other products in the pipeline are based on a unique umbilical cord blood expansion platform developed at the Fred Hutchinson Cancer Research Center
SyntheZyme develops bio-based products and technologies with a unique and competitive cost/performance. We work closely together with our industrial partners for the manufacture and marketing of our bio-based commodity and specialty products for the global market. We seek to complement our core competencies with those of our strategic, industrial partners. The success of our business is based on our capabilities to structure and operate entrepreneurial partnerships. SyntheZyme’s scientists and engineers have a deep knowledge in chemistry, synthetic biology, fermentation engineering and materials science with process know-how
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.